Home

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Antibodies

Chemical Structure Cat. No. Product Name CAS No.
Disitamab Vedotin Chemical Structure
BCP44433 Disitamab Vedotin 2136633-23-1
Iodine (131I) Derlotuximab Biotin Chemical Structure
BCP44109 Iodine (131I) Derlotuximab Biotin 340013-96-9
Otilimab Chemical Structure
BCP44143 Otilimab 1638332-55-4
Otilimab is a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor.
Stamulumab Chemical Structure
BCP44146 Stamulumab 705287-60-1
Stamulumab (MYO-029) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD).
Metelimumab Chemical Structure
BCP44140 Metelimumab 272780-74-2
Metelimumab is a human IgG4 monoclonal antibody developed as a TGFβ1-specific antagonist.
Mapatumumab Chemical Structure
BCP44137 Mapatumumab 658052-09-6
Mapatumumab is a fully human monoclonal antibody that is agonistic to the TRAIL Receptor 1 (TRAIL-R1).
Lexatumumab Chemical Structure
BCP44135 Lexatumumab 845816-02-6
Lexatumumab, a human agonistic monoclonal antibody against tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2), is a promising molecular-targeted therapeutic agent.
Lerdelimumab Chemical Structure
BCP44133 Lerdelimumab 285985-06-0
Lerdelimumab, a monoclonal antibody to transforming growth factor-beta2 (TGF-beta2).
Fresolimumab Chemical Structure
BCP44132 Fresolimumab 948564-73-6
Fresolimumab is an antibody capable of neutralizing all human isoforms of transforming growth factor beta (TGFβ) and has demonstrated anticancer activity in investigational studies
Tralokinumab Chemical Structure
BCP44131 Tralokinumab 1044515-88-9
Tralokinumab is a human monoclonal antibody that neutralises interleukin 13.
123下一页末页共 141 条记录 1 / 15 页 
0086-15971444841